ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Chlorhexidine 0.02% treatment for refractory blepharoconjunctivitis.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the efficacy and safety of twice daily 0.02% Chlorhexidine in treating chronic refractory blepharoconjunctivitis.
methodsA case series of 10 patients with symptomatic, chronic, and resistant-to-treatment bilateral blepharoconjunctivitis were referred to our clinic. Conjunctival swab cultures were obtained, anterior segment photographs were taken, and all patients began treatment with 0.02% chlorhexidine administered twice daily. Clinical signs and symptoms were monitored over the follow-up period.
resultsOf ten patients (20 eyes, mean age was 67.6 +/- 19.05 years), 6/10 had positive cultures of a resistant strain of Staphylococcus aureus or epidermidis previously treated with topical antibiotic drops. All patients showed complete resolution of conjunctival hyperemia and reported substantial improvement of symptoms after 2 weeks of treatment. At 1-month follow-up, the patients reported complete resolution of symptoms. Best corrected visual acuity (BCVA) before and after treatment differences were not statistically significant.
conclusionTwice-daily application of 0.02% chlorhexidine appears to be a safe and effective treatment for patients with chronic, treatment-resistant blepharoconjunctivitis, offering significant symptomatic relief and clinical improvement.
Indexed as
Identifiers
41201626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.